Research
Hormonal
Metformin treatment led to a significant decrease in the IGF-1:IGFBP3 molar ratio by 0.0119 at 3 months compared to self-directed weight loss.
Metformin may effectively reduce the IGF-1:IGFBP3 molar ratio in cancer survivors, indicating a potential benefit in hormonal regulation.
StrongSupportsmedium confidence
Participants in metformin had significant decreases on IGF-1 (mean difference in change: -5.50 ng/mL, P = 0.02) and IGF1:IGFBP3 molar ratio (mean difference in change: -0.0119, P = 0.011) at 3 months.
Why this rating
Based on the randomized controlled trial design.
Source
Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial
Hsin‐Chieh Yeh et al. · The Journal of Clinical Endocrinology & Metabolism · 2021
DOI 10.1210/clinem/dgab266
rct · n=121Cited 22×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →